29 July 2025
Pfizer's 20-valent pneumococcal conjugate vaccine (PCV20), now approved in Malaysia for people aged 6 weeks and older, covers 20 disease-causing pneumococcal serotypes, including seven additional strains linked to antibiotic resistance and high mortality.